2 weeks Ago By ABMN Staff
Verona Pharma plc ( NASDAQ:VRNA – Get Free Report ) was the recipient of a significant increase in short interest in August. As of August 15th, there was short interest totalling 10,700,000 shares, an increase of 21.0% from the July 31st total of 8,840,000 shares.
Based on an average daily volume of 1,480,000 shares, the days-to-cover ratio is presently 7.2 days. Wall Street Analyst Weigh In A number of research analysts recently weighed in on VRNA shares.
Canaccord Genuity Group raised their target price on shares of Verona Pharma from $35.00 to $37.00 and gave the company a “buy” rating in a report on Monday, July 22nd.
HC Wainwright raised their price target on Verona Pharma from $32.00 to $36.00 and gave the stock a “buy” rating in a research report on Thursday, June 27th.
Finally, Truist Financial raised their price target on Verona Pharma from $32.00 to $38.00 and gave the stock a “buy” rating in a research report on Friday, June 28th.
Five research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the company has a consensus rating of “Buy” and a consensus price target of $36.00. Read Our Latest Stock Report on Verona Pharma Institutional Trading of Verona Pharma Verona Pharma Stock Up 5.
7 % Shares of VRNA opened at $27.48 on Friday. The company has a market cap of $2.
20 billion, a PE ratio of -35.69 and a beta of 0.44.
The business has a fifty day moving average of $21.84 and a 200 day moving average of $17.56.
Verona Pharma has a 52-week low of $11.39 and a 52-week high of $28.83.
The company has a quick ratio of 8.61, a current ratio of 8.61 and a debt-to-equity ratio of 0.
72. Verona Pharma ( NASDAQ:VRNA – Get Free Report ) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.
88) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.35) by ($0.53).
During the same period in the prior year, the company posted ($0.11) earnings per share. On average, sell-side analysts expect that Verona Pharma will post -2.
07 EPS for the current year. Verona Pharma Company Profile ( Get Free Report ) Verona Pharma plc, a clinical stage biopharmaceutical company, focuses on development and commercialization of therapies for the treatment of respiratory diseases with unmet medical needs. The company's product candidate is ensifentrine, an inhaled and dual inhibitor of the phosphodiesterase (PDE) 3 and PDE4 enzymes that acts as both a bronchodilator and an anti-inflammatory agent in a single compound, which is in Phase 3 clinical trials for the treatment of chronic obstructive pulmonary disease, asthma, and cystic fibrosis.
Further Reading Receive News & Ratings for Verona Pharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Verona Pharma and related companies with MarketBeat.com's FREE daily email newsletter ..
